Texas Capital Bancshares Inc
Change company Symbol lookup
Select an option...
TCBI Texas Capital Bancshares Inc
IBB iShares Nasdaq Biotechnology ETF
NEP Nextera Energy Partners LP
FRAN Francesca's Holdings Corp
CDTI CDTi Advanced Materials Inc
UBER Uber Technologies Inc
MTX Minerals Technologies Inc
PRGS Progress Software Corp
CODA Coda Octopus Group Inc
WAB Westinghouse Air Brake Technologies Corp
Go

Financials : Banks | Small Cap Growth
Company profile

Texas Capital Bancshares, Inc. is a bank holding and a financial holding company. The Company is the parent of Texas Capital Bank, National Association (the Bank). It offers a range of loan, deposit account and other financial products and services to its customers. It offers a range of products and services for its business customers, including commercial loans for general corporate purposes, including financing for working capital, internal growth, acquisitions and financing for business insurance premiums; medium- and long-term tax-exempt loans for municipalities and other governmental and tax-exempt entities; wealth management and trust services, and letters of credit. It also provides banking services for its individual customers, including personal wealth management and trust services; certificates of deposit; interest-bearing and non-interest-bearing checking accounts; traditional money market and savings accounts; loans, both secured and unsecured, and Internet banking.

Postmarket

Last Trade
Delayed
$38.75
0.23 (0.60%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$38.52
Day's Change
1.21 (3.24%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
38.84
Day's Low
37.15
Volume
(Heavy Day)
Volume:
464,851

10-day average volume:
341,646
464,851

Shares of Roche gain as it says arthritis drug can lessen need for ventilators in COVID-19 patients

7:42 am ET September 18, 2020 (MarketWatch)
Print

Shares of Roche Holding AG gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than those receiving placebo. The Phase 3, randomized, double-blind, placebo-controlled study focused on enrolling minority patients with COVID-19-related pneumonia; there are 389 participants enrolled in the trial. However, the drug did not lead to a difference in mortality, Roche said. Roche is also testing Actemra with Gilead Sciences Inc.'s (GILD) remdesivir, which is the only new drug to receive an emergency use authorization from the Food and Drug Administration as a COVID-19 treatment during the pandemic. Earlier this week Eli Lilly & Co. (LLY) and Incyte Corp. (INCY) said their rheumatoid arthritis drug Olumiant when paired with remdesivir (http://www.marketwatch.com/story/shares-of-lilly-and-incyte-gain-after-late-stage-study-finds-their-arthritis-drug-can-help-reduce-covid-19-recovery-time-2020-09-14%7CNEW) shortened recovery time for hospitalized coronavirus patients. Both findings, neither of which have been published yet in a peer-reviewed medical journal, for the first time in months point to a clinical benefit for rheumatoid arthritis drugs when treating some COVID-19 patients after a series of setbacks (http://www.marketwatch.com/story/sanofi-regeneron-kevzara-fails-in-late-stage-covid-19-trial-2020-09-01) over the summer. Shares of Roche have gained 16.4% so far this year. Shares of Roche have gained 16.4% so far this year, while the S&P 500 is up 3.9%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 18, 2020 07:42 ET (11:42 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.